莫西沙星与左氧氟沙星治疗社区获得性肺炎的Meta分析  

Meta-Analysis of two drugs in the Treatment for Community-Acquired Pneumonia

作　　者：林文宏[1] 卢海燕[1] 饶智辉[1] 

机构地区：[1]福建医科大学附属龙岩第一医院药剂科,福建省龙岩市364000

出　　处：《中华全科医学》2014年第1期101-103,共3页Chinese Journal of General Practice

摘　　要：目的 比较莫西沙星与左氧氟沙星治疗中国人群社区获得性肺炎（CAP）的疗效和安全性.方法 采用Meta分析的方法对有关奠西沙星与左氧氟沙星治疗中国人群CAP的临床疗效、细菌学疗效和不良反应发生率进行汇总分析.结果 共纳入11项随机对照研究.Meta分析结果显示2组有效率比较差异具有统计学意义（Z=6.21,P＜0.01,OR =2.91,95％ CI 2.07.4.07）;2组细菌学疗效比较差异具有统计学意义（Z =4.91,P＜0.01,OR=2.97,95％ CI 1.92～4.58）;2组不良反应发生率比较差异无统计学意义（Z=0.71,P=0.48,OR=0.86,95％CI0.56～1.31）.Begg＆#39;s检验和Egger＆#39;s检验显示无发表性偏倚.结论 莫西沙星治疗中国人群CAP的疗效要高于左氧氟沙星,但两者安全性相当.Objective To compare the effects and safety of moxifloxacin and levofloxacin in the treatment for community- acquired pneumonia（CAP） in China. Methods The data of random controlled trials （RCTs） about moxifloxacin and levofloxacin on CAP were analyzed by Meta-analysis method to evaluate the clinical efficacy, bacteriological efficacy and incidence of adverse reaction. Results 11 RCTs were included into this study. Meta-analysis showed that the two groups had significant differences in clinical efficacy （Z =6.21 ,P 〈0.01 ,OR =2.91,95% C1 2.07 -4.07） and bacteriological efficacy （ Z = 4.91, P 〈 0.01, OR = 2.97,95 % CI 1.92 - 4.58 ）. While, the incidences of adverse reaction between the the groups were similar （ Z = 0.71, P = 0.48, OR = 0.86,95 % CI 0.56 - 1.31 ）. No significant publication bias was found by Begg＇ s test and Egger＇ s test. Conclusion The effects were higher in Chinese CAP patients treated by moxifloxacin than levofloxacin. But the safety was similar.

关 键 词：莫西沙星 左氧氟沙星 社区获得性肺炎 META分析 

分 类 号：R563.1[医药卫生—呼吸系统] R978.19[医药卫生—内科学]